Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Ocular Therapeutix (OCUL) Invested Capital (2016 - 2025)

Historic Invested Capital for Ocular Therapeutix (OCUL) over the last 13 years, with Q4 2025 value amounting to $654.3 million.

  • Ocular Therapeutix's Invested Capital rose 10749.09% to $654.3 million in Q4 2025 from the same period last year, while for Dec 2025 it was $654.3 million, marking a year-over-year increase of 10749.09%. This contributed to the annual value of $654.3 million for FY2025, which is 10749.09% up from last year.
  • Per Ocular Therapeutix's latest filing, its Invested Capital stood at $654.3 million for Q4 2025, which was up 10749.09% from $258.2 million recorded in Q3 2025.
  • Over the past 5 years, Ocular Therapeutix's Invested Capital peaked at $654.3 million during Q4 2025, and registered a low of $3.1 million during Q2 2023.
  • For the 5-year period, Ocular Therapeutix's Invested Capital averaged around $188.7 million, with its median value being $104.1 million (2021).
  • Its Invested Capital has fluctuated over the past 5 years, first crashed by 9530.87% in 2023, then surged by 1213501.78% in 2024.
  • Over the past 5 years, Ocular Therapeutix's Invested Capital (Quarter) stood at $120.9 million in 2021, then tumbled by 39.72% to $72.9 million in 2022, then soared by 76.49% to $128.6 million in 2023, then soared by 145.15% to $315.3 million in 2024, then skyrocketed by 107.49% to $654.3 million in 2025.
  • Its Invested Capital stands at $654.3 million for Q4 2025, versus $258.2 million for Q3 2025 and $305.9 million for Q2 2025.